Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Tanghe, An ^a   Termont, Annelies ^a   Merchiers, Pascal ^b   Schilling, Stephan ^c   Demuth, Hans Ulrich ^c   Scrocchi, Louise ^d   Van Leuven, Fred ^e   Griffioen, Gerard ^a   Van Dooren, Tom ^a  

^a ReMYND NV   (Belgium)

^b ABLYNX NV   (Belgium)

^c PROBIODRUG AG   (Germany)

^d Amorfix Life Sciences   (Canada)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; POLYGLUTAMINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; MEMORY DISORDER; MOUSE; NONHUMAN; OLIGOMERIZATION; ORIENTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYMPTOM; TRANSGENIC MOUSE;

EID: 77957859638     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/417314     Document Type: Article

References (43)

1. Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., Devijver H., Van Leuven F., Amyloid activates GSK-3 to aggravate neuronal tauopathy in bigenic mice American Journal of Pathology 2008 172 3 786 798
2. Oddo S., Caccamo A., Kitazawa M., Tseng B. P., LaFerla F. M., Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease Neurobiology of Aging 2003 24 8 1063 1070
3. Hardy J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal Journal of Neurochemistry 2009 110 4 1129 1134
4. Torres-Aleman I., Mouse models of Alzheimer's dementia: current concepts and new trends Endocrinology 2008 149 12 5952 5957
5. Jaworski T., Dewachter I., Seymour C. M., Alzheimer's disease: old problem, new views from transgenic and viral models Biochimica et Biophysica Acta 2010 1802 10 808 818
6. Geerts H., Of mice and men: bridging the translational disconnect in CNS drug discovery CNS Drugs 2009 23 11 915 926
7. Epis R., Gardoni F., Marcello E., Genazzani A., Canonico P. L., Di Luca M., Searching for new animal models of Alzheimer′s disease European Journal of Pharmacology 2010 626 1 57 63
8. Radde R., Duma C., Goedert M., Jucker M., The value of incomplete mouse models of Alzheimer's disease European Journal of Nuclear Medicine and Molecular Imaging 2008 35 1 S70 S74
9. Moechars D., Dewachter I., Lorent K., Revers D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van Den Haute C., Checler F., Godaux E., Cordell B., Van Leuven F., Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain Journal of Biological Chemistry 1999 274 10 6483 6492 (Pubitemid 29111064)
10. Terwel D., Lasrado R., Snauwaert J., Vandeweert E., Van Haesendonck C., Borghgraef P., Van Leuven F., Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice Journal of Biological Chemistry 2005 280 5 3963 3973
11. Dewachter I., Van Dorpe J., Smeijers L., Gilis M., Kuipri C., Laenen I., Caluwaerts N., Moechars D., Checler F., Vanderstichele H., Van Leuven F., Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1 Journal of Neuroscience 2000 20 17 6452 6458
12. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M. P., Beard J., Das P., Jansen K., DeLucia M., Lin W.-L., Dolios G., Wang R., Eckman C. B., Dickson D. W., Hutton M., Hardy J., Golde T., A 42 is essential for parenchymal and vascular amyloid deposition in mice Neuron 2005 47 2 191 199
13. Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes Acta Neuropathologica 1991 82 4 239 259
14. Thal D. R., Rb U., Orantes M., Braak H., Phases of A -deposition in the human brain and its relevance for the development of AD Neurology 2002 58 12 1791 1800
15. Duyckaerts C., Delatour B., Potier M.-C., Classification and basic pathology of Alzheimer disease Acta Neuropathologica 2009 118 1 5 36
16. Eikelenboom P., Veerhuis R., Familian A., Hoozemans J. J. M., Van Gool W. A., Rozemuller A. J. M., Neuroinflammation in plaque and vascular -amyloid disorders: clinical and therapeutic implications Neurodegenerative Diseases 2008 5 3-4 190 193
17. Dorpe J. V., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., Van Leuven F., Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons American Journal of Pathology 2000 157 4 1283 1298
18. Gilbert J. J., Vinters H. V., Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage Stroke 1983 14 6 915 923
19. Prelli F., Castano E., Glenner G. G., Frangione B., Differences between vascular and plaque core amyloid in Alzheimer's disease Journal of Neurochemistry 1988 51 2 648 651
20. Pype S., Moechars D., Dillen L., Mercken M., Characterization of amyloid peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein Journal of Neurochemistry 2003 84 3 602 609
21. Miravalle L., Calero M., Takao M., Roher A. E., Ghetti B., Vidal R., Amino-terminally truncated A peptide species are the main component of cotton wool plaques Biochemistry 2005 44 32 10810 10821
22. Saido T. C., Iwatsubo T., Mann D. M. A., Shimada H., Ihara Y., Kawashima S., Dominant and differential deposition of distinct -amyloid peptide species, A N3(pE), in senile plaques Neuron 1995 14 2 457 466
23. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.-U., Bayer T. A., Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model Acta Neuropathologica 2009 118 4 487 496
24. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.-U., Rossner S., Glutaminyl cyclase inhibition attenuates pyroglutamate A and Alzheimer's disease-like pathology Nature Medicine 2008 14 10 1106 1111
25. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K., Prediction of Alzheimer's disease using the CSF A 42/A 40 ratio in patients with mild cognitive impairment Dementia and Geriatric Cognitive Disorders 2007 23 5 316 320
26. Lewczuk P., Esselmann H., Otto M., Maler J. M., Henkel A. W., Henkel M. K., Eikenberg O., Antz C., Krause W.-R., Reulbach U., Kornhuber J., Wiltfang J., Neurochemical diagnosis of Alzheimer's dementia by CSF A 42, A 42/A 40 ratio and total tau Neurobiology of Aging 2004 25 3 273 281
27. Shoji M., Kanai M., Matsubara E., Tomidokoro Y., Shizuka M., Ikeda Y., Ikeda M., Harigaya Y., Okamoto K., Hirai S., The levels of cerebrospinal fluid A 40 and A 42(43) are regulated age-dependently Neurobiology of Aging 2001 22 2 209 215
28. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojiro E., Prinzen C., Endres K., Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., Van Leuven F., Fahrenholz F., A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model Journal of Clinical Investigation 2004 113 10 1456 1467
29. Dewachter I., Filipkowski R. K., Priller C., Ris L., Neyton J., Croes S., Terwel D., Gysemans M., Devijver H., Borghgraef P., Godaux E., Kaczmarek L., Herms J., Van Leuven F., Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice Neurobiology of Aging 2009 30 2 241 256
30. Domnguez-Del-Toro E., Rodrguez-Moreno A., Porras-Garca E., Snchez-Campusano R., Blanchard V., Laville M., Bhme G. A., Benavides J., Delgado-Garca J. M., An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease European Journal of Neuroscience 2004 20 7 1945 1952
31. Moechars D., Gilis M., Kuipri C., Laenen I., Van Leuven F., Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs Neuroreport 1998 9 16 3561 3564
32. Larner A. J., Epileptic seizures in AD Patients Neuromolecular Medicine 2010 12 1 71 77
33. Palop J. J., Mucke L., Epilepsy and cognitive impairments in alzheimer disease Archives of Neurology 2009 66 4 435 440
34. Markesbery W. R., Neuropathologic alterations in mild cognitive impairment: a review Journal of Alzheimer's Disease 2010 19 1 221 228
35. Tomic J. L., Pensalfini A., Head E., Glabe C. G., Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction Neurobiology of Disease 2009 35 3 352 358
36. Eikelenboom P., van Exel E., Hoozemans J. J.M., Veerhuis R., Rozemuller A. J.M., van Gool W. A., Neuroinflammationan early event in both the history and pathogenesis of Alzheimer's disease Neurodegenerative Diseases 2010 7 13 38 41
37. Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., Van Leuven F., Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice Journal of Neuroinflammation 2005 2, article 22
38. Meilandt W. J., Cisse M., Ho K., Wu T., Esposito L. A., Scearce-Levie K., Cheng I. H., Yu G.-Q., Mucke L., Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice Journal of Neuroscience 2009 29 7 1977 1986
39. Koh S.-H., Noh M. Y., Kim S. H., Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3 Brain Research 2008 1188 1 254 262
40. Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G.-Q., Mucke L., Reducing endogenous tau ameliorates amyloid -induced deficits in an Alzheimer's disease mouse model Science 2007 316 5825 750 754
41. Dewachter I., Revers D., Caluwaerts N., Ris L., Kuipri C., Van Den Haute C., Spittaels K., Umans L., Serneels L., Thiry E., Moechars D., Mercken M., Godaux E., Van Leuven F., Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice Journal of Neuroscience 2002 22 9 3445 3453
42. Citron M., Eckman C. B., Diehl T. S., Corcoran C., Ostaszewski B. L., Xia W., Levesque G., Hyslop P. ST. G., Younkin S. G., Selkoe D. J., Additive effects of PS1 and APP mutations on secretion of the 42- residue amyloid -protein Neurobiology of Disease 1998 5 2 107 116
43. Spittaels K., Van Den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F., Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein American Journal of Pathology 1999 155 6 2153 2165